Mielite transversa

Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002 Aug 27;59(4):499-505. Resumo

Sechi E, Shosha E, Williams JP, et al. Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. Neurology. 2019 Jul 23;93(4):e414-20. Resumo

de Seze J, Lanctin C, Lebrun C, et al. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology. 2005 Dec 27;65(12):1950-3. Resumo

Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin Proc. 2017 Apr;92(4):663-79.Texto completo  Resumo

Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999 Dec;46(6):878-86. Resumo

Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: plasmapheresis in neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011 Jan 18;76(3):294-300.Texto completo  Resumo

Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018 Apr 24;90(17):777-88.Texto completo  Resumo

1. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002 Aug 27;59(4):499-505. Resumo

2. Beh SC, Greenberg BM, Frohman T, et al. Transverse myelitis. Neurol Clin. 2013 Feb;31(1):79-138.Texto completo  Resumo

3. Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005 May;4(5):281-8. Resumo

4. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999 Sep 22;53(5):1107-14. Resumo

5. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006 Mar;59(3):566-9. Resumo

6. Scott TF. Nosology of idiopathic transverse myelitis syndromes. Acta Neurol Scand. 2007 Jun;115(6):371-6. Resumo

7. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002 Jan 17;346(3):158-64.Texto completo  Resumo

8. Wingerchuk DM. Immune-mediated myelopathies. Continuum (Minneap Minn). 2018 Apr;24(2, spinal cord disorders):497-522. Resumo

9. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007 Sep;6(9):805-15. Resumo

10. Berman M, Feldman S, Alter M, et al. Acute transverse myelitis: incidence and etiologic considerations. Neurology. 1981 Aug;31(8):966-71. Resumo

11. Jeffery DR, Mandler RN, Davis LE. Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events. Arch Neurol. 1993 May;50(5):532-5. Resumo

12. Christensen PB, Wermuth L, Hinge HH, et al. Clinical course and long-term prognosis of acute transverse myelopathy. Acta Neurol Scand. 1990 May;81(5):431-5. Resumo

13. Altrocchi PH. Acute transverse myelopathy. Arch Neurol. 1963 Aug;9:111-9. Resumo

14. Farkkila M, Tiainen T, Koskiniemi M. Epidemiology and prognosis of acute myelitis in Southern Finland. J Neurol Sci. 1997 Nov 25;152(2):140-6. Resumo

15. Beghi E, Kurland LT, Mulder DW. Incidence of acute transverse myelitis in Rochester, Minnesota, 1970-1980, and implications with respect to influenza vaccine. Neuroepidemiology. 1982;1:176-88.

16. Sechi E, Shosha E, Williams JP, et al. Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. Neurology. 2019 Jul 23;93(4):e414-20. Resumo

17. Zalewski NL, Flanagan EP, Keegan BM. Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses. Neurology. 2018 Jan 9;90(2):e96-e102. Resumo

18. Compston A, Coles A. Multiple sclerosis. Lancet. 2008 Oct 25;372(9648):1502-17. Resumo

19. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol. 2003 Feb;2(2):117-27. Resumo

20. Chabas D, Strober G, Waubant E. Pediatric multiple sclerosis. Curr Neurol Neurosci Rep. 2008 Sep;8(5):434-41. Resumo

21. Banwell B, Tenembaum S, Lennon VA, et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology. 2008 Jan 29;70(5):344-52. Resumo

22. McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology. 2008 Jul 8;71(2):93-100. Resumo

23. Jacob A, Weinshenker BG. An approach to the diagnosis of acute transverse myelitis. Semin Neurol. 2008 Feb;28(1):105-20.Texto completo  Resumo

24. de Seze J, Lanctin C, Lebrun C, et al. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology. 2005 Dec 27;65(12):1950-3. Resumo

25. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med. 2006 Mar 2;354(9):942-55. Resumo

26. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004 Dec 11-17;364(9451):2106-12. Resumo

27. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005 Aug 15;202(4):473-7.Texto completo  Resumo

28. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007 Dec 11;69(24):2221-31. Resumo

29. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002 Jul;125(Pt 7):1450-61.Texto completo  Resumo

30. Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin Proc. 2017 Apr;92(4):663-79.Texto completo  Resumo

31. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014 Feb 11;82(6):474-81.Texto completo  Resumo

32. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012 Sep 18;79(12):1273-7. Resumo

33. Krishnan C, Kaplin AI, Deshpande DM, et al. Transverse myelitis: pathogenesis, diagnosis and treatment. Front Biosci. 2004 May 1;9:1483-99. Resumo

34. Pidcock FS, Krishnan C, Crawford TO, et al. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology. 2007 May 1;68(18):1474-80. Resumo

35. Deshpande DM, Krishnan C, Kerr DA. Transverse myelitis after lumbar steroid injection in a patient with Behcet's disease. Spinal Cord. 2005 Dec;43(12):735-7. Resumo

36. Martinez-Garcia E, Pelaez E, Roman JC, et al. Transverse myelitis following general and epidural anaesthesia in a paediatric patient. Anaesthesia. 2005 Sep;60(9):921-3. Resumo

37. Frohman EM, Wingerchuk DM. Clinical practice. Transverse myelitis. N Engl J Med. 2010 Aug 5;363(6):564-72. Resumo

38. de Seze J, Stojkovic T, Breteau G, et al. Acute myelopathies: clinical, laboratory and outcome profiles in 79 cases. Brain. 2001 Aug;124(Pt 8):1509-21.Texto completo  Resumo

39. Dubey D, Pittock SJ, Krecke KN, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019 Mar 1;76(3):301-9.Texto completo  Resumo

40. Huh SY, Kim SH, Hyun JW, et al. Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders. Mult Scler. 2017 Mar;23(3):413-19. Resumo

41. Flanagan EP, Weinshenker BG, Krecke KN, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol. 2015 Jan;72(1):81-7.Texto completo  Resumo

42. Flanagan EP, Keegan BM. Paraneoplastic myelopathy. Neurol Clin. 2013 Feb;31(1):307-18. Resumo

43. Zalewski NL, Krecke KN, Weinshenker BG, et al. Central canal enhancement and the trident sign in spinal cord sarcoidosis. Neurology. 2016 Aug 16;87(7):743-4.Texto completo  Resumo

44. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 May 23;66(10):1485-9. Resumo

45. Bennett JL, de Seze J, Lana-Peixoto M, et al. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler. 2015 May;21(6):678-88.Texto completo  Resumo

46. Scott TF, Kassab SL, Singh S. Acute partial transverse myelitis with normal cerebral magnetic resonance imaging: transition rate to clinically definite multiple sclerosis. Mult Scler. 2005 Aug;11(4):373-7. Resumo

47. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000 Sep 28;343(13):898-904.Texto completo  Resumo

48. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006 Oct 10;67(7):1242-9. Resumo

49. Sellner J, Luthi N, Buhler R, et al. Acute partial transverse myelitis: risk factors for conversion to multiple sclerosis. Eur J Neurol. 2008 Apr;15(4):398-405. Resumo

50. Deiva K, Absoud M, Hemingway C, et al; United Kingdom Childhood Inflammatory Demyelination (UK-CID) Study and French Kidbiosep Study. Acute idiopathic transverse myelitis in children: early predictors of relapse and disability. Neurology. 2015 Jan 27;84(4):341-9. Resumo

51. Ropper AH, Poskanzer DC. The prognosis of acute and subacute transverse myelopathy based on early signs and symptoms. Ann Neurol. 1978 Jul;4(1):51-9. Resumo

52. Al-Araji AH, Oger J. Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler. 2005 Aug;11(4):398-402. Resumo

53. Savoldi F, Nasr Z, Hu W, et al. McArdle sign: a specific sign of multiple sclerosis. Mayo Clin Proc. 2019 Aug;94(8):1427-35. Resumo

54. Waubant E, Alize P, Tourbah A, et al. Paroxysmal dystonia (tonic spasm) in multiple sclerosis. Neurology. 2001 Dec 26;57(12):2320-1. Resumo

55. Misu T, Fujihara K, Nakashima I, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005 Nov 8;65(9):1479-82. Resumo

56. Takahashi T, Miyazawa I, Misu T, et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry. 2008 Sep;79(9):1075-8. Resumo

57. Pittock SJ, Weinshenker BG, Wijdicks EF. Mechanical ventilation and tracheostomy in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004 Sep;75(9):1331-3.Texto completo  Resumo

58. Filippi M, Rocca MA, Ciccarelli O, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016 Mar;15(3):292-303.Texto completo  Resumo

59. Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016 Sep 26;13(1):279.Texto completo  Resumo

60. Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016 Sep 27;13(1):280.Texto completo  Resumo

61. Berger JR, Sabet A. Infectious myelopathies. Semin Neurol. 2002 Jun;22(2):133-42. Resumo

62. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008 Jan;65(1):78-83.Texto completo  Resumo

63. Fang B, McKeon A, Hinson SR, et al. Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol. 2016 Nov 1;73(11):1297-1307.Texto completo  Resumo

64. Hoitsma E, Faber CG, Drent M, et al. Neurosarcoidosis: a clinical dilemma. Lancet Neurol. 2004 Jul;3(7):397-407. Resumo

65. Schmidt MH, Klimo P Jr, Vrionis FD. Metastatic spinal cord compression. J Natl Compr Canc Netw. 2005 Sep;3(5):711-9. Resumo

66. McDonald JW, Sadowsky C. Spinal-cord injury. Lancet. 2002 Feb 2;359(9304):417-25. Resumo

67. Cheshire WP, Santos CC, Massey EW, et al. Spinal cord infarction: etiology and outcome. Neurology. 1996 Aug;47(2):321-30. Resumo

68. Jellema K, Tijssen CC, van Gijn J. Spinal dural arteriovenous fistulas: a congestive myelopathy that initially mimics a peripheral nerve disorder. Brain. 2006 Dec;129(Pt 12):3150-64.Texto completo  Resumo

69. Koehler PJ, Verbiest H, Jager J, et al. Delayed radiation myelopathy: serial MR-imaging and pathology. Clin Neurol Neurosurg. 1996 May;98(2):197-201. Resumo

70. Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005 Jul;58(1):96-107. Resumo

71. Han JJ, Massagli TL, Jaffe KM. Fibrocartilaginous embolism - an uncommon cause of spinal cord infarction: a case report and review of the literature. Arch Phys Med Rehabil. 2004 Jan;85(1):153-7. Resumo

72. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol. 2008 Oct;7(10):939-50. Resumo

73. Kumar N. Copper deficiency myelopathy (human swayback). Mayo Clin Proc. 2006 Oct;81(10):1371-84. Resumo

74. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89.Texto completo  Resumo

75. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-73. Resumo

76. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999 Dec;46(6):878-86. Resumo

77. Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: plasmapheresis in neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011 Jan 18;76(3):294-300.Texto completo  Resumo

78. Krishnan C, Kaplin AI, Pardo CA, et al. Demyelinating disorders: update on transverse myelitis. Curr Neurol Neurosci Rep. 2006 May;6(3):236-43. Resumo

79. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 31;374(9700):1503-11. Resumo

80. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018 Apr 24;90(17):777-88.Texto completo  Resumo

81. Yavin Y, Cohen AT. Venous thromboembolism prophylaxis for the medical patient: where do we stand? Semin Respir Crit Care Med. 2008 Feb;29(1):75-82. Resumo

82. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998 Oct;51(4):1219-20. Resumo

83. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005 Apr 12;64(7):1270-2. Resumo

84. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008 Nov;65(11):1443-8. Resumo

85. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol. 2008 Jan;10(1):55-66. Resumo

86. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019 Aug 15;381(7):614-25.Texto completo  Resumo

87. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019 Oct 12;394(10206):1352-63. Resumo

88. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019 Nov 28;381(22):2114-24. Resumo

89. Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020 May;19(5):402-12. Resumo

90. Dunne K, Hopkins IJ, Shield LK. Acute transverse myelopathy in childhood. Dev Med Child Neurol. 1986 Apr;28(2):198-204. Resumo